How about enroll me in this research at the University of Oregon in Portland ? Is
it near Seattle ? ..... ;))

lv,
j



Ed Grskovich wrote:

> Posted at: AOL Business
>
> NeoTherapeutics Completes Site Selection for Neotrofin(TM) Phase 2
> Parkinson's Disease Trial
>
> Patient enrollment accelerating with expanded program
>
> IRVINE, Calif., Aug. 23 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: <A
> HREF="aol://4785:NEOT">NEOT</A>; NEOTW) announced today that it has expanded
> its Neotrofin phase 2 Parkinson's disease trial to include four additional
> clinical locations. New participants include Memorial Hospital of Rhode
> Island (Providence), Rush Presbyterian-St. Luke's Medical Center (Chicago),
> The Parkinson's Institute (Sunnyvale, CA), and Oregon Health & Science
> University (Portland). Ten patients are currently receiving either Neotrofin
> or placebo, including seven patients at the Parkinson's and Movement Disorder
> Institute at Long Beach Memorial Hospital.
>
> "With site selection completed, we can now focus on enrolling the additional
> patients necessary to complete this clinical study," said F. Jacob Huff,
> M.D., Vice President, Medical Affairs of NeoTherapeutics. "We are fortunate
> to be working with some of the leading experts in the country in the
> treatment of Parkinson's disease, and we expect to gain insights into safety
> and dosing in Parkinson's patients from this study."
>
> "Neotrofin uses the body's own tools to protect, repair and rebuild nerves in
> the brain," stated Rajesh C. Shrotriya, M.D., President and Chief Operating
> Officer of NeoTherapeutics.  "Our drug activates nerve growth factors, which
> in addition to helping repair nerves, cause the proliferation of stem cells
> that already exist in the brain. Additional growth factors stimulated by
> Neotrofin may then cause the differentiation and maturation of these new stem
> cells into new neurons, which could repair the damage done by
> neurodegenerative conditions such as Parkinson's disease."
>
> Patients participating in this trial will receive doses of Neotrofin
> escalating from 250 mg to 1,000 mg twice per day for twelve weeks. In
> addition to extensive assessments of tolerance and safety, the Unified
> Parkinson's Disease Rating Scale (UPDRS)-part III (Motor Scale) will be used
> as the primary measure of preliminary efficacy. Several other Parkinson's
> disease rating scales will be used as secondary efficacy measures.
>
> Parkinson's disease is one of the major neurodegenerative disorders affecting
> more than one million patients in North America alone. The principal
> hallmarks of Parkinson's disease are slowness of movement, rigidity and
> tremor. Although current treatments provide some symptomatic relief,
> Parkinson's disease progresses inexorably, often over 10 to 20 years, to
> severe immobility and a bedridden state.
>
> NeoTherapeutics seeks to create value for stockholders through the
> development of central nervous system drugs by its neurology division, in-
> licensing and development of anti-cancer drugs through its NeoOncoRx
> subsidiary, and the licensing out of new drug targets through its NeoGene
> Technologies subsidiary. The Company's most advanced drug, Neotrofin(TM), is
> currently being developed for Alzheimer's disease and other neurodegenerative
> diseases, such as Parkinson's disease and spinal cord injury. For additional
> information visit the Company's web site at www.neotherapeutics.com.
>
> This press release may contain forward-looking statements regarding future
> events and the future performance of NeoTherapeutics that involve risks and
> uncertainties that could cause actual results to differ materially.  These
> risks are described in further detail in the Company's reports filed with the
> Securities and Exchange Commission.
>
> Contacts:
>
> MEDIA RELATIONS
>
> Jon Siegal
>
> Ronald Trahan Associates (RTA) Inc.
>
> (508) 647-9782, ext. 15
>
> INVESTOR RELATIONS
>
> John McManus
>
> NeoTherapeutics, Inc.
>
> (949) 788-6700, ext. 247
>
> MAKE YOUR OPINION COUNT -  Click Here
>
> http://tbutton.prnewswire.com/prn/11690X72818987
>
> SOURCE  NeoTherapeutics, Inc.
>
> CO:  NeoTherapeutics, Inc.
>
> ST:  California
>
> IN:  MTC
>
> SU:
>
> 08/23/2001 09:15 EDT http://www.prnewswire.com

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn